MSC ExosomesInterpret the evidence
Why an exosome study and an FDA approval are separate records
3 numbered sourcesSource years 2020–2026
Peptides are short chains of amino acids linked by peptide bonds. Cells can use them as messages. MSC exosomes are a type of extracellular vesicle released by mesenchymal stromal cells. They are particles with a membrane, rather than a single peptide. In a February 2026 warning letter, the FDA addressed the status of certain products marketed as exosomes for medical purposes. [1] [2]
The agency explained that exosome products intended to diagnose, treat or prevent disease, or affect the structure or function of the body, generally fall under applicable requirements for drugs and biological products. The letter addressed products offered by a specific business. The agency's earlier consumer alert explained that it had not approved exosome products at the time of the alert. These records describe how the agency addresses therapeutic claims and products. They provide a public record of the agency's position at the time each document was issued. [1] [3]
A clinical study is a separate record. It may give researchers a way to examine what happens with a defined material under an investigational framework. Its existence does not establish that FDA has reviewed and approved that material for an indication. Commercial products using a related name also may differ from a research preparation in what they contain. [1] [2] [3]
The terms in a promotional description, clinical paper and regulatory record can overlap. The wording alone cannot establish approval. Each record serves a different purpose. Reading the specific product name, intended use and approval status together is necessary to know which regulatory decision, if any, the record describes. [1] [3]
Sources
Original works cited in this article. Links open the external record in a new tab.
